Since the initial approval of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) for clinical use in 1991, our understanding of these agents has grown substantially. Laboratory investigation, clinical trials, and outcomes research have all been of pivotal importance to our knowledge base. Equally important has been the parallel process of guidelines development, initially through ASCO and subsequently with ESMO and other societies.
Of note, the FDA approved this agent based on a biologic license application because the process of approval for biosimilars is still under review. In a related article in this issue, Drs. Bradford R. Hirsch and Gary H. Lyman address biosimilars in oncology more broadly. The authors discuss models of the possible economic impact of tbo-filgrastim versus filgrastim versus biosilimar filgrastim, based on a European analysis. What clinical and economic impact will occur in the United States as this agent becomes available is still to be seen. However, a broader menu of agents will certainly stimulate more competition, more interest, and more research, all of which will ultimately be good for the field of oncology and for our patients.
Another new section of the NCCN Guidelines this year is our initial recommendations regarding the use of myeloid growth factors in the hematopoietic cell transplant setting. I am grateful to Dr. Pamela Becker and her subcommittee, who helped formulate these initial guidelines. We look forward to feedback from the NCCN Member Institutions and the guidelines readership for comments and suggestions on how we might further improve this section, and the guidelines overall.
Much has been written about evidence-based versus consensus-based guidelines. In my mind, there is clearly a role for both, building on the evidence base with consensus recommendations from the expert panel. We all recognize the potential risks of consensus-based guidelines if they are not firmly rooted in evidence; however, in many clinical situations, evidence often stops short of providing useful guidance. The NCCN Guidelines process allows correction and refinement of both the evidence base and consensus base from broad input, providing an ideal balance on an ongoing basis.
Finally, I have had the privilege of serving as Chair of the NCCN Myeloid Growth Factors Panel since its inception, and have been continuously impressed by the knowledge, thoughtful decision-making, and commitment of the members of the panel to our process of continual improvement. The physicians and pharmacists on our committee, with support from an outstanding NCCN administrative staff, provide an impressive range of expertise across all the areas of hematology-oncology so relevant to myeloid growth factors and their proper use. I would like to take this opportunity to personally thank all of the panel members for their ongoing efforts.
